TipRanks
Biofrontera AG (GB:0DOL)
LSE:0DOL
UK Market
0DOL
Biofrontera
RESEARCH TOOLSreports

Biofrontera (0DOL) Ratios

0 Followers

Biofrontera Ratios

GB:0DOL's free cash flow for Q4 2023 was €0.81. For the 2023 fiscal year, GB:0DOL's free cash flow was decreased by € and operating cash flow was €0.09. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Mar 24Mar 23
Liquidity Ratios
Current Ratio
 1.18 2.43 ― 1.76 1.80
Quick Ratio
 1.08 1.77 ― 1.26 1.22
Cash Ratio
 0.44 0.63 ― 0.31 0.76
Solvency Ratio
 -0.32 -0.57 ― 0.04 -3.50
Operating Cash Flow Ratio
 -0.75 -0.77 ― -0.19 -0.46
Short-Term Operating Cash Flow Coverage
 0.00 -7.14 ― -4.10 -8.73
Net Current Asset Value
€ -5.67M€ 8.11M€ ―€ 6.97M€ 2.67M
Leverage Ratios
Debt-to-Assets Ratio
 0.31 0.03 ― 0.04 0.05
Debt-to-Equity Ratio
 1.26 0.04 ― 0.06 0.07
Debt-to-Capital Ratio
 0.56 0.04 ― 0.05 0.07
Long-Term Debt-to-Capital Ratio
 0.44 0.00 ― 0.03 0.05
Financial Leverage Ratio
 4.04 1.38 ― 1.54 1.61
Debt Service Coverage Ratio
 -24.38 -9.97 ― 15.18 2.27
Interest Coverage Ratio
 -18.81 -73.21 ― 318.80 9.75
Debt to Market Cap
 0.36 0.04 ― <0.01 <0.01
Interest Debt Per Share
 0.60 0.11 ― 0.02 0.03
Net Debt to EBITDA
 -0.51 5.32 ― -0.35 -2.09
Profitability Margins
Gross Profit Margin
84.45%82.71%―78.67%81.52%
EBIT Margin
-13.52%-9.16%―14.83%6.18%
EBITDA Margin
-12.19%-4.25%―17.28%9.08%
Operating Profit Margin
-9.45%-7.77%―14.83%6.18%
Pretax Profit Margin
-13.72%-9.27%―15.93%-167.88%
Net Profit Margin
-13.78%-30.06%―-1.14%-171.60%
Continuous Operations Profit Margin
-13.78%-52.64%―-1.14%-171.60%
Net Income Per EBT
100.46%324.47%―-7.18%102.21%
EBT Per EBIT
145.19%119.22%―107.44%-2717.61%
Return on Assets (ROA)
-26.45%-19.21%―-1.20%-134.96%
Return on Equity (ROE)
-127.78%-26.60%―-1.85%-217.18%
Return on Capital Employed (ROCE)
-32.27%-6.87%―23.15%6.53%
Return on Invested Capital (ROIC)
-31.18%-6.58%―22.08%6.42%
Return on Tangible Assets
-29.61%-19.21%―-1.25%-140.09%
Earnings Yield
-48.52%-26.74%―-0.07%-2.40%
Efficiency Ratios
Receivables Turnover
 8.33 2.19 ― 4.38 11.61
Payables Turnover
 1.34 1.56 ― 2.65 2.40
Inventory Turnover
 6.54 0.61 ― 1.36 0.99
Fixed Asset Turnover
 9.32 19.98 ― 9.80 8.55
Asset Turnover
 1.92 0.64 ― 1.05 0.79
Working Capital Turnover Ratio
 22.36 1.89 ― 4.51 14.38
Cash Conversion Cycle
 -172.89 532.40 ― 215.08 247.09
Days of Sales Outstanding
 43.83 166.43 ― 83.35 31.44
Days of Inventory Outstanding
 55.78 599.69 ― 269.35 367.92
Days of Payables Outstanding
 272.50 233.73 ― 137.62 152.26
Operating Cycle
 99.61 766.12 ― 352.69 399.36
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.61 -0.72 ― -0.03 -0.07
Free Cash Flow Per Share
 -0.61 -0.73 ― -0.04 -0.08
CapEx Per Share
 <0.01 <0.01 ― 0.01 0.02
Free Cash Flow to Operating Cash Flow
 1.00 1.01 ― 1.48 1.25
Dividend Paid and CapEx Coverage Ratio
 -2.64K -86.27 ― -2.10 -3.97
Capital Expenditure Coverage Ratio
 -2.64K -86.27 ― -2.10 -3.97
Operating Cash Flow Coverage Ratio
 -1.06 -7.03 ― -1.67 -2.59
Operating Cash Flow to Sales Ratio
 -0.17 -0.33 ― -0.06 -0.15
Free Cash Flow Yield
-61.02%-30.02%―-0.53%-0.26%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -1.69 -3.75 ― -1.45K -41.60
Price-to-Sales (P/S) Ratio
 0.28 1.12 ― 16.66 71.53
Price-to-Book (P/B) Ratio
 2.20 0.99 ― 26.89 90.53
Price-to-Free Cash Flow (P/FCF) Ratio
 -1.64 -3.33 ― -189.91 -377.55
Price-to-Operating Cash Flow Ratio
 -1.65 -3.37 ― -280.26 -472.64
Price-to-Earnings Growth (PEG) Ratio
 >-0.01 0.39 ― 14.63 0.19
Price-to-Fair Value
 2.20 0.99 ― 26.89 90.53
Enterprise Value Multiple
 -2.81 -21.16 ― 96.06 785.64
Enterprise Value
 15.84M 11.85M ― 535.32M 1.84B
EV to EBITDA
 -2.81 -21.16 ― 96.06 785.64
EV to Sales
 0.34 0.90 ― 16.60 71.34
EV to Free Cash Flow
 -2.00 -2.66 ― -189.23 -376.55
EV to Operating Cash Flow
 -2.00 -2.69 ― -279.25 -471.39
Tangible Book Value Per Share
 0.26 2.44 ― 0.30 0.33
Shareholders’ Equity Per Share
 0.46 2.45 ― 0.31 0.35
Tax and Other Ratios
Effective Tax Rate
 >-0.01 -4.68 ― -0.34 -0.02
Revenue Per Share
 3.57 2.17 ― 0.51 0.45
Net Income Per Share
 -0.49 -0.65 ― >-0.01 -0.77
Tax Burden
 1.00 3.24 ― -0.07 1.02
Interest Burden
 1.02 1.01 ― 1.07 -27.16
Research & Development to Revenue
 0.06 0.17 ― 0.24 0.28
SG&A to Revenue
 0.86 0.72 ― 0.41 0.48
Stock-Based Compensation to Revenue
 0.02 0.00 ― 0.00 0.00
Income Quality
 1.25 -2.14 ― 5.20 0.09
Currency in EUR